Understanding a drug’s mechanism of action (MOA) can greatly increase the likelihood of successful clinical trials by identifying biomarkers of patient response and providing a rationale for ...

Dave Lahr, PhD, is currently leading the computational biology group at Foghorn Therapeutics, a biotech startup focused on treating diseases by correcting abnormal gene expression. In the early days ...

In a recent study published in npj Antimicrobials and Resistance, researchers addressed the issue of the rise of antifungal drugs-resistant infections and the advent of multidrug-resistant fungal ...

Malaria represents one of the most serious threats to human health worldwide, and preventing and curing this parasitic disease still depends predominantly on the administration of a small number of ...

New cell biology data from Europe shows simufilam interrupts a pathogenic signaling pathway in Alzheimer’s disease. Results corroborate prior research from other academic researchers. These data once ...

The 2026 Informal Scientific Network (ISN) meeting, held on the margins of the 69th Commission on Narcotic Drugs (CND), brought together more than 30 leading scientists to advance global understanding ...

Silo Pharma, Inc. has announced the filing of a patent application for its neurology drug, SPC-14, which is an intranasal treatment for Alzheimer's disease. This compound, licensed from Columbia ...

A team from the University of Barcelona has designed and validated in animal models an innovative compound with a pioneering ...

Ovarian cancer treatment faces challenges with high relapse and drug resistance rates, despite initial chemotherapy effectiveness. Cytokines like IL-6 and IL-11 are associated with complex tumor ...